Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.60 |
| ▸ | TLR2 | O60603 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001931 | 1.00 | TLR4 (0.60) | TLR4TLR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL510517 | 0.88 | TLR4 (0.75) | TLR4TLR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1106891 | 0.88 | TLR4 (0.75) | TLR4TLR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2991930 | 0.83 | ALDH1A1 (0.73) | TLR4TLR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13248546 | 0.77 | PARP10 (0.49) | KDM4EALDH1A1SMN1; SMN2HPGDPARP10 | |
| SCHEMBL2251349 | 0.76 | PARP10 (0.57) | KDM4EALDH1A1SMN1; SMN2HPGDPARP10 | |
| SCHEMBL2992851 | 0.76 | PARP10 (0.57) | KDM4EALDH1A1SMN1; SMN2PARP10MAOA | |
| SCHEMBL2246114 | 0.75 | FFAR1 (0.49) | KDM4EALDH1A1SMN1; SMN2HPGDPARP10 | |
| SCHEMBL510139 | 0.75 | TLR4 (1.00) | TLR4TLR2MAOAMAOB | |
| SCHEMBL3005551 | 0.75 | MAOB (0.47) | KDM4EALDH1A1SMN1; SMN2HPGDPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | TLR4 687/4885TLR2 348/4885KDM4E 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.